欧洲和加拿大成人特应性皮炎患者报告疾病负担的横断面研究
该横断面研究纳入加拿大和欧洲临床实践中的成人特应性皮炎(AD)患者,按严重度分为轻度(547例)、中度(520例)、重度(400例),比较患者报告的瘙痒、疼痛、睡眠、生活质量及焦虑抑郁负担。结果显示重度AD患者多领域负担显著高于中轻度,且对环孢素或系统免疫调节剂存在疗效不足/不耐受/禁忌的亚组负担与重度组相似。
要点
- 重度AD患者瘙痒、疼痛、睡眠障碍及焦虑抑郁均显著高于中轻度。
- 重度AD的DLQI均分16.2,对生活质量影响大,高于中度10.2和轻度5.5。
- 环孢素或系统免疫调节剂亚组的负担与重度AD患者总体相似。
核心结论
- 成人AD患者在多个领域存在显著负担,重度患者负担显著更高。
- 对环孢素或系统免疫调节剂疗效不足/不耐受/禁忌的亚组负担与重度AD相似。
研究设计与样本
- 横断面研究,纳入加拿大和欧洲临床实践中经皮肤科医生、全科医生或过敏科医生诊断的18-65岁成人AD患者。
- 按研究者整体评估(IGA)分为轻度(n=547;37.3%)、中度(n=520;35.4%)、重度(n=400;27.3%)。
- 另按对环孢素(Cyclo;n=62)和任何系统免疫调节剂(IMM;n=104)的疗效不足/不耐受/禁忌分层,并与排除Cyclo/IMM的重度组比较。
主要发现
- 重度AD患者合并症更多、瘙痒和疼痛更重、睡眠更差、焦虑抑郁水平更高(均P < 0.001)。
- 重度AD的DLQI均分(16.2 ± 6.9)高于中度(10.2 ± 6.3)和轻度(5.5 ± 4.9)(均P < 0.001)。
- 女性比例在轻度组高于重度组(61.2% vs. 50.5%;P < 0.001)。
- Cyclo和IMM亚组的负担总体上与重度AD患者相似。
关键数值与推荐
- 重度AD的DLQI均分16.2 ± 6.9,中度10.2 ± 6.3,轻度5.5 ± 4.9(均P < 0.001)。
- 重度AD与中轻度比较,瘙痒、疼痛、睡眠、焦虑抑郁差异均P < 0.001。
- 女性比例轻度组61.2% vs. 重度组50.5%(P < 0.001)。
临床怎么用
- 临床评估成人AD时应关注瘙痒、疼痛、睡眠及焦虑抑郁等多领域负担。
- 对环孢素或系统免疫调节剂疗效不足/不耐受/禁忌的患者,其负担可能与重度AD相当,需积极管理。
局限性
- 横断面设计无法推断因果关系。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cross-sectional data on patient burden in adults with atopic dermatitis (AD) from real-world clinical practice are limited. OBJECTIVE: This study compared patient-reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This study included adults (18-65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient-Oriented-Scoring of Atopic Dermatitis (PO-SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. RESULTS: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. CONCLUSIONS: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD.
引用
- de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020. PMID: 31587373. doi:10.1111/jdv.16003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。